EDX Medical Group’s Post

Yesterday at #ASCO24, Shasqi’s Founder & CEO, José M. Mejía Oneto presented data from our Phase 2a study in patients with soft tissue sarcoma. This trial represents the first successful dose escalation of doxorubicin beyond 4x in a clinical trial: using our CAPAC technology to activate chemotherapy at the tumor, we were able to dose 12x the standard dose of doxorubicin per cycle without any DLTs, and with mild and manageable myelosuppression. Thanks to our PIs: Nam Bui, Vineet Kwatra, Christopher W. Ryan, MD, Erlinda Maria Gordon MD and Sant Chawla and to the patients and their families for participating in this study. Read the full poster here👇 https://bit.ly/3VpEuHR

🔬 Insights from ASCO 2024! Prof Mariana Brandao from Institut Jules Bordet presents the latest ctDNA analysis from the ADAURA trial on adjuvant osimertinib in resected stage I-III NSCLC. The study suggests that ctDNA monitoring could help tailor treatment duration, potentially reducing toxicity and improving patient quality of life. Discover the implications for clinical practice. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #LungCancer #OncologyInnovation #ADAURATrial #ctDNA

Now more than ever, we are reminded how the safety of our ADG126 SAFEbody and its best-in-class profile is translating to better patient outcomes, including clinical response and survival. With a safety profile comparable to pembrolizumab monotherapy, the ADG126 + pembrolizumab doublet is well positioned to become a new cornerstone #IO therapy that can be broadly combined, addressing indications and patient populations beyond the IO agents available today! With its unique mechanism and ability to target CTLA-4 on Tregs in the tumor microenvironment, ADG126 is designed to take #CTLA-4 to a new level. Check out our publications showcasing its 10x higher combination dosing than ipilimumab, and unique ability to dose more frequently @Q3W and repeatedly beyond 4 cycles: https://loom.ly/m_8X16s

Curious about what awaits you at #ECIO2024? Visit us at booth #19 and discover: ▪ how ARTIS icono ceiling with Xpand* adds an extra level of freedom and flexibility to your angio suite. ▪ how integrated laser guidance can simplify CT-guided interventions with myNeedle Companion on SOMATOM X.ceed and SOMATOM X.cite. ▪ how our cryoablation and embolization solutions are designed for truly targeted procedures to empower improved patient outcomes. ▪ our new ablation confirmation software myAblation Guide**. ▪ the patient journey from screening to follow-up with our virtual liver cancer patient, Ben.   And that’s not all. Don’t miss the opportunity to join our Satellite Symposium on April 29 and take part in our interactive hands-on sessions. 👉 Check the detailed program https://lnkd.in/d2dqBgVk   #siemenshealthineers #interventionaloncology  *Xpand does not yet fulfill all applicable General Safety and Performance Requirements according to the European Medical Device Regulation 2017/745. It is not yet commercially available in the European Union.  **myAblation Guide is pending 510(k) clearance, and not yet commercially available in the United States.  

Curious about what awaits you at #ECIO2024? Visit my colleagues at booth #19 and discover: ▪ how ARTIS icono ceiling with Xpand* adds an extra level of freedom and flexibility to your angio suite. ▪ how integrated laser guidance can simplify CT-guided interventions with myNeedle Companion on SOMATOM X.ceed and SOMATOM X.cite. ▪ how our cryoablation and embolization solutions are designed for truly targeted procedures to empower improved patient outcomes. ▪ our new ablation confirmation software myAblation Guide**. ▪ the patient journey from screening to follow-up with our virtual liver cancer patient, Ben.   And that’s not all. Don’t miss the opportunity to join our Satellite Symposium on April 29 and take part in our interactive hands-on sessions. 👉 Check the detailed program https://lnkd.in/gEkPd9Wx   #siemenshealthineers #interventionaloncology  *Xpand does not yet fulfill all applicable General Safety and Performance Requirements according to the European Medical Device Regulation 2017/745. It is not yet commercially available in the European Union.  **myAblation Guide is pending 510(k) clearance, and not yet commercially available in the United States.  

Curious about what awaits you at #ECIO2024? Visit us at booth #19 and discover: ▪ how ARTIS icono ceiling with Xpand* adds an extra level of freedom and flexibility to your angio suite. ▪ how integrated laser guidance can simplify CT-guided interventions with myNeedle Companion on SOMATOM X.ceed and SOMATOM X.cite. ▪ how our cryoablation and embolization solutions are designed for truly targeted procedures to empower improved patient outcomes. ▪ our new ablation confirmation software myAblation Guide**. ▪ the patient journey from screening to follow-up with our virtual liver cancer patient, Ben.   And that’s not all. Don’t miss the opportunity to join our Satellite Symposium on April 29 and take part in our interactive hands-on sessions. 👉 Check the detailed program https://lnkd.in/d5GU9Mbj   #siemenshealthineers #interventionaloncology  *Xpand does not yet fulfill all applicable General Safety and Performance Requirements according to the European Medical Device Regulation 2017/745. It is not yet commercially available in the European Union.  **myAblation Guide is pending 510(k) clearance, and not yet commercially available in the United States. 

🚀 **Exciting Milestone: First Collaboration Agreement Signed!** We are thrilled to announce the signing of TRUEinvivo Limited's first collaboration agreement with the International Stereotactic Radiosurgery Society (ISRS) and MEDICAL PHYSICS LIMITED! This partnership brings together innovative dosimetry solutions by TRUEinvivo with ISRS's expertise in intracranial Stereotactic Radiosurgery (SRS) Certification Services. For investors, this is a significant step forward in expanding our market presence globally. Clinicians can now access enhanced dosimetric evaluations to ensure precise and safe treatments. Most importantly, cancer patients requiring radiosurgery will benefit from cutting-edge, reliable quality assurance that supports better treatment outcomes. Together, we are setting a new standard in radiosurgery safety and precision. #HealthcareInnovation #Radiosurgery #CancerTreatment #InvestorUpdates #PatientSafety

🚨 Exciting News! 🚨 We are thrilled to announce that the NanoKnife System has received FDA clearance for prostate indication! This groundbreaking advancement in irreversible electroporation (IRE) technology now offers a non-invasive option for treating prostate tissue. This clearance opens new doors for patients and healthcare professionals alike, offering an innovative, effective solution with minimal recovery time. The NanoKnife System represents a major leap forward in precision treatment, expanding options for patients around the world. Our commitment to improving patient outcomes is stronger than ever, and this new FDA-cleared indication is just the beginning! We extend our gratitude to the dedicated healthcare professionals, researchers, and patients who have been part of this journey. Learn more: https://lnkd.in/eU9PKwxh Risk Info: https://lnkd.in/gFNG_pA *The indications, contraindications, and product availability for the NanoKnife System varies by region. Refer to Instructions for Use and/or User Manual provided with the product within your specific region for complete Instructions, Warnings, Precautions, Potential Complications and Contraindications prior to use of the product. Not all products are available, registered, or marketed in all regions. Individual results may vary. #NanoKnife #MedicalInnovation #MedTech #IRE #Electroporation #PatientCare #Oncology #Prostate

Curious about what awaits you at #ECIO2024? Visit us at booth #19 and discover: ▪how ARTIS icono ceiling with Xpand* adds an extra level of freedom and flexibility to your angio suite. ▪ how integrated laser guidance can simplify CT-guided interventions with myNeedle Companion on SOMATOM X.ceed and SOMATOM X.cite. ▪ how our cryoablation and embolization solutions are designed for truly targeted procedures to empower improved patient outcomes. ▪ our new ablation confirmation software myAblation Guide**. ▪ the patient journey from screening to follow-up with our virtual liver cancer patient, Ben.   And that’s not all. Don’t miss the opportunity to join our Satellite Symposium on April 29 and take part in our interactive hands-on sessions. 👉 Check the detailed program https://lnkd.in/eSw5PPuZ   #siemenshealthineers #interventionaloncology *Xpand does not yet fulfill all applicable General Safety and Performance Requirements according to the European Medical Device Regulation 2017/745. It is not yet commercially available in the European Union. **myAblation Guide is pending 510(k) clearance, and not yet commercially available in the United States.  

⭐️ Thanks to Shirish Gadgeel, MD, for sharing his insights on the ARROS-1 and ALKOVE-1 trial data presented at #ESMO24! ➡️ Watch the interview to learn more about the phase 1/2 trials and the next steps: https://buff.ly/3BGw47q #lcsm #NSCLC #ESMO2024 #lungcancer